Brief: NanoViricides Says NV-387 Effective In Protecting Lungs From Damage In Lethally Infected Animal Model
20/06/2024 11:42
June 20 (Reuters) - NanoViricides Inc NNVC.A :
* NANOVIRICIDES INC: ULTRA-BROAD-SPECTRUM ANTIVIRAL NV-387,
CLINICAL PHASE II STAGE DRUG CANDIDATE, WAS FOUND EFFECTIVE IN
PROTECTING LUNGS FROM DAMAGE
* NANOVIRICIDES INC: NV-387 TREATMENT RESULTED IN
SIGNIFICANT
REDUCTION IN LUNG INFILTRATION AND LUNG CELL DEATH
* NANOVIRICIDES INC: NV-387 TREATMENT SIGNIFICANTLY
PROTECTED
LUNGS OF BALB-C MICE LETHALLY INFECTED WITH INFLUENZA A/H3N2
VIRUS
* NANOVIRICIDES INC: NV-387 TREATMENT RESULTED IN
SIGNIFICANT
REDUCTION IN MUCUS LOAD IN LUNGS
Further company coverage: NNVC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NanoViricides,
See all newsExplainer: What do we know about the Bundibugyo strain of the Ebola virus?
Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments